Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Milvexian + Aspirin DDI Study
NCT03341390Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Oct 2017
- Primary completion
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in thromboembolism and ischemic stroke comparing Milvexian + Aspirin with Placebo + Aspirin (2 arms). Primary endpoints: Number of participants with non-serious Adverse Events (AEs) and Serious Adverse Events (SAEs) leading to discontinuation up to 10 days, Number of potential clinically significant changes in electrical activity of the heart up to 10 days and 3 more. Started Oct 2017; status: completed.
02
Drugs
milvexian
03
Conditions
thromboembolismischemic stroke
Beyond the preview
Go deeper on NCT03341390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03341390.